7:08 PM
 | 
Apr 19, 2005
 |  BC Extra  |  Clinical News

Eximias enrolls Thymitaq Phase III

Eximias (Berwyn, Penn.) completed enrollment of 446 patients in the open-label, international, Phase III ETHECC trial of Thymitaq...

Read the full 73 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >